4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the “Company”) dated 30 June 2023 at 07:30 hours CEST concerning an offer to buy back shares (the “Offer”) in connection with its Long Term Incentive Plan (LTIP) for the executive management. The Offer expired Monday 3 July 2023 at 16:00 hours CEST.
The Company has resolved to buy back 220 000 shares at a price of NOK 23,00 per share (the “Purchase Price”). The Purchase Price was determined through a reverse book-building process conducted by SpareBank 1 Markets AS.
As a result of the buy back, the Company owns 220 000 own shares, corresponding to 0,50% of the share capital and voting rights in the Company.
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each…
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…